+49 30 648 35 164 service@chameleon-pharma.com

Mex­ico has dou­bled its eco­nomic growth within the last ten years and is cur­rently ranked as the sec­ond-most lead­ing mar­ket econ­omy in Cen­tral Amer­ica. In the last year, lead­ing index MEXBOL increased by 11%. In com­par­i­son, the Brazil­ian BOVESPA has only man­aged 2.8%.

Mex­ico is one of the most densely pop­u­lated coun­tries in the world. Within the last few years, the standard of living there has improved tremen­dously; life expectancy, as well as the num­ber of per­sons aged over sixty-five, has increased, thus inten­si­fy­ing the demand for Pharma prod­ucts. Due to new reg­u­la­tions, the health­care sys­tem has also become much more patient-friendly. As a result, the Pharma mar­ket has increased by more than 8% per year. This means that the size of the Pharma mar­ket is esti­mated to rise to US $22.5 bil­lion by 2020.

Brazil also has a rapidly grow­ing mar­ket, but the country’s ANVISA** reg­u­la­tions are so stringent that any mar­ket access for new health­care prod­ucts has the poten­tial to cre­ate prob­lems. More­over, patient han­dling has become so casual that high num­bers of claims are common.

Colom­bia, Chile and Argentina are also viewed as coun­tries with poten­tial, and despite not reach­ing the level of the TRIUMPH markets, they can occa­sion­ally offer middle-sized com­pa­nies some inter­est­ing niche opportunities.

CPC Press Releases on Mexico:

Mexico: Healthcare Emerging Market